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Abstract 
 
Aims: To identify risk factors for major Adverse Events (AEs) and to develop a nomogram 
to predict the probability of such AEs in individual patients who have surgery for apparent 
early stage endometrial cancer.  
Methods: We used data from 753 patients who were randomized to either total laparoscopic 
hysterectomy or total abdominal hysterectomy in the LACE trial. Serious adverse events that 
prolonged hospital stay or postoperative adverse events (using common terminology criteria 
3+, CTCAE V3) were considered major AEs. We analyzed pre-surgical characteristics that 
were associated with the risk of developing major AEs by multivariate logistic regression. 
We identified a parsimonious model by backward stepwise logistic regression. The six most 
significant or clinically important variables were included in the nomogram to predict the risk 
of major AEs within 6 weeks of surgery and the nomogram was internally validated.  
Results: Overall, 132 (17.5%) patients had at least one major AE. An open surgical approach 
(laparotomy), higher Charlson’s medical co-morbidities score, moderately differentiated 
tumours on curettings, higher baseline ECOG score, higher body mass index and low 
haemoglobin levels were associated with AE and were used in the nomogram. The bootstrap 
corrected concordance index of the nomogram was 0.63 and it showed good calibration.   
Conclusions: Six pre-surgical factors independently predicted the risk of major AEs. This 
research might form the basis to develop risk reduction strategies to minimize the risk of AEs 
among patients undergoing surgery for apparent early stage endometrial cancer.   
Clinical Trial Registration: NCT00096408 
Keywords: Endometrial cancer; safety; surgery; risk factors 
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Introduction 
Endometrial cancer represents a significant health issue for women in developed countries 
and its incidence is still rising (1). Advanced age and an oversupply of endogenous or 
exogenous oestrogen are the most common and well established risk factors for endometrial 
cancer and patients often receive treatment for obesity, diabetes mellitus and hypertension (2-
5). Treatment of endometrial cancer is primarily surgical, generally yielding excellent 
survival outcomes (6).  
Traditionally, surgery has been performed through a laparotomy (Total Abdominal 
Hysterectomy; TAH), which is associated with significant morbidity. Results from our 
randomized controlled trial comparing TAH with total laparoscopic hysterectomy (TLH) (the 
LACE trial) found that patients undergoing TLH reported significantly better postsurgical 
improvement in Quality of Life (QoL) compared to TAH (7). This improvement in QoL 
continued to favour a laparoscopic approach for up to 6 months post-surgery. Previous 
findings from the US Gynecologic Oncology Group  (GOG) LAP2 trial suggest a lower 
incidence of surgical adverse events (AEs) in uterine cancer patients who received 
laparoscopic compared to open surgery (8). In contrast, the recently published Dutch TLH 
trial suggested a similar rate of surgical complications in laparoscopic and open surgery for 
early endometrial cancer and endometrial hyperplasia with atypia (9).  
In this issue, we have reported that the incidence of AEs was significantly reduced in patients 
receiving TLH compared to TAH (Obermair et al, submitted for publication). The results 
suggest that the surgical approach is a potentially modifiable risk factor for AEs, but the risk 
factors leading to surgical complications are largely unknown.  
Therefore, it was the aim of this manuscript to identify the risk factors associated with AEs in 
patients undergoing surgery for apparent early stage endometrial cancer. In addition, we 
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developed a nomogram to predict a patient’s individual risk to develop a major AE based on 
pre-surgical characteristics. 
 
Patients and Methods 
Between October 2005 and June 2010, a total of 760 women with apparent stage I 
endometrial cancer was enrolled into the LACE trial (clinicaltrials.gov id: NCT00096408). 
Its study design, data on early surgical recovery and postoperative QoL as well as data on the 
surgical safety of TLH were reported previously (7, 10). In brief, patients were randomized to 
either TLH or TAH using stratified permuted blocks through a web-based system with 
concealment of the next allocated treatment to study staff. Ethical clearance was obtained 
from all the relevant hospitals where patients were recruited and all the patients had provided 
written informed consent. 
Women were eligible if they had histologically confirmed endometrioid endometrial 
adenocarcinoma (irrespective of histological grade), disease apparently confined to the uterus 
and ECOG performance status of zero or one. Patients had to have medical imaging of the 
pelvis, abdomen and the chest to suggest the absence of extrauterine disease. Patients had a 
comprehensive surgical staging except those with grade 1 or grade 2 tumours with 
myometrial invasion up to the inner half, patients who were unfit for a lymph node dissection 
because of medical reasons or morbidly obese patients. All trial surgeons had to go through 
an accreditation process to ensure the highest possible surgical standard. The surgical 
technique was described in detail previously (11).  
A comprehensive surgical and medical history was taken prior to surgery. Medical Co-
morbidities were recorded, classified and scored according to Charlson et al (12). Patients 
also completed questionnaires on relevant social and demographic variables. Patients were 
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followed-up for at least 6 weeks for any adverse event. Post-operative adverse events (AEs) 
were recorded using the NCI Common Terminology Criteria for Adverse Events v3.0 (CTC 
AE). Serious AEs were defined as any event that resulted in death, was immediately life 
threatening, required inpatient hospitalization or prolongation of an existing hospitalization or 
that resulted in persistent or significant disability/incapacity. All serious AEs were reviewed 
by an independent safety committee. All the AEs were managed by respective clinicians/co-
investigators as per their local guidelines and patients were followed-up until satisfactory 
resolution or until the principal investigator or co-investigator deemed the event to be chronic 
or the patient was assessed to be stable. A “major AE” was defined as either a postoperative 
AE of CTC Grade 3+ and/or a serious AE as defined above. For the aim of this analysis, the 
incidence of a “major AE” was considered an endpoint.  
Statistical analyses 
Patients who had completed at least 6 weeks of follow-up after surgery were included. 
Univariate logistic regression analysis was used to test for associations between the incidence 
of major AEs and relevant clinical and demographic factors. Due to the skewed distribution 
of CA-125, neutrophil count, bilirubin and alanine transaminase (ALT), these variables were 
log (natural) transformed and evaluated. Variables that showed significant association with 
major AEs were used in a multivariate logistic regression with stepwise model selection. 
Risk-factors were also evaluated for significant interactions. Height and or weight were 
missing for 27 patients (3.5%) and these patients were excluded in multivariate models that 
utilized body mass index as a predictor. No data were imputed. Treatment effects were 
analysed according to the intention to treat principle. 
A nomogram was developed to predict the risk of major AEs within 6 weeks of surgery using 
the entire dataset. The following variables available prior to surgery formed part of the 
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nomogram: planned surgical approach (TAH vs TLH), Charlson’s comorbidity score (12), 
grade of curettings ((International Federation of Gynecology and Obstetrics (FIGO) grades 1, 
2 or 3), Eastern Cooperative Oncology Group (ECOG) score (0 vs 1), Body Mass Index 
(BMI) (<25, 25 to < 30, 30 to < 35, 35 to < 40 and 40+) and haemoglobin levels. The 
predicted probability was calculated for each patient based on the nomogram, which was then 
assessed for its ability to discriminate among patients, as quantified by the concordance 
index. This concordance index is equivalent to the area under the receiver operating 
characteristic (ROC) curve. A value of 0.5 indicates no discrimination ability and 1 
represents perfect separation of patients with different outcomes.  To correct for 
overestimation, bootstrapping was performed with 1000 replications and the nomogram was 
calibrated to improve predictions on external datasets. Statistical analyses were performed 
using SAS 9.2 or Stata version 11.2. Nomogram was generated using R version 2.13.2 (R 
Development Core Team, 2011) with ‘rms’ package added. Statistical significance was set at 
the level of 0.05. 
 
Results 
A total of 760 patients were enrolled in the LACE trial between 2005 and 2010. Of these, 
four patients withdrew after randomization but prior to surgery and an additional three 
patients withdrew from the trial one week after surgery. Of a total of 753 evaluable patients 
with at least 6 weeks of follow-up, 349 were randomly allocated to treatment with TAH, and 
404 to treatment with TLH. Treatment groups were balanced in terms of relevant 
demographic and clinical factors and descriptive AE data are also shown elsewhere 
(Obermair et al, submitted for publication in this issue). A total of 117 (15%) patients had at 
least one post-operative AE with CTC Grade 3+, and 83 (11%) patients had at least one 
serious AE. One hundred and thirty two patients (17%) had a major AE.  
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Univariate logistic regression analysis showed that allocation to TAH, increasing Charlson’s 
comorbidity score, increasing BMI, increasing ECOG performance score, higher grade of 
curettings, low baseline haemoglobin levels and elevated aspartate transaminase levels were 
associated with risk of a major AE, while age at diagnosis, and other blood status factors did 
not attain statistical significance (Table 2).  
On multivariable analysis, treatment allocation to TAH, increasing Charlson’s medical co-
morbidity score, poor grade of differentiation on curettings  (FIGO grade 2 or 3),  high BMI 
and low preoperative haemoglobin level remained independently significant for major AEs 
(p<0.05). Figure 1 shows the nomogram to predict major AEs. To allow risk prediction, 
points were allocated to each of the predictor variables. The sum of all the points for a patient 
corresponds to a predicted probability of a major AE. Initial modelling showed a concordance 
index of 0.68. Internal validation with 1000 bootstrap resamples showed our model to over-
predict by 4.5%. The model was recalibrated and achieved a bias-corrected concordance 
index of 0.65 for predicting a major AE.  
Figure 2 shows in a graphical format, how closely the predictions from the nomogram 
compare with actual outcomes for patients in this study. Values on the x-axis represent the 
prediction calculated with use of the nomogram and those on the y-axis represent the actual 
data for our patients. The dashed diagonal line represents the performance of an ideal 
nomogram, where predicted outcome perfectly matches with actual outcome. 
 
Discussion 
We present a simple algorithm in the form of a nomogram to estimate an individual patient’s 
risk of developing a major surgical AE following TLH or TAH for apparent early 
endometrial cancer prior to surgery. Parameters available before surgery and found to be 
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independently associated with an increased risk of major AE in patients presenting with 
apparently stage I endometrial cancer include an open surgical approach through laparotomy, 
a higher Charlson’s medical co-morbidity score at baseline, advanced FIGO grade of 
curettings, higher BMI and low haemoglobin levels prior to surgery.  
Adverse events during or following a surgical procedure are not uncommon, especially in 
high risk specialties such as surgical oncology. The published incidence of adverse events 
among patients with gynaecological cancer varies from 26% to 54% (13, 14) and some 
studies suggest that a significant portion of AEs are preventable (15-17).  
The present manuscript suggests that major AEs are partly predictable. The planned surgical 
approach was one of the potentially modifiable risk factors. Choosing a laparoscopic 
approach to surgery for endometrial cancer reduced the risk of major surgical AEs by at least 
46% after adjusting for other prognostic factors. Moderately differentiated curettings and low 
preoperative haemoglobin independently contributed to the risk of major AEs. The 
preoperative ECOG performance status was also included in the model but only scarce 
literature is available on the role of ECOG performance status and its impact on the risk of 
surgical adverse events in endometrial cancer. However, performance status has been shown 
to be related to clinical outcomes including survival in other cancers (18-24).  
Obesity was reported to be a risk factor for postoperative AEs previously, especially in 
patients who require a laparotomy (25, 26). In the Dutch TLH trial (9), increasing age and 
BMI were significantly associated with an increased risk of major complications regardless of 
the surgical approach. In the LACE trial, higher BMI increased the risk for major AEs. 
However, age was not an important factor for major AEs. 
The Charlson’s index is a weighted index that considers the number and severity of medical 
co-morbid conditions. It was developed on a cohort of 559 medical patients in 1987 (12) and 
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was shown to estimate the risk of death from those medical co-morbidities. Previously we 
described the influence of the presence of malignancy, complexity of surgery, American 
Association of Anaesthetists score and BMI on the risk of AEs in a heterogeneous patient 
population with proven or suspected gynaecological cancer (14). In contrast, the present work 
describes the influence of the Charlson’s index as a standardised tool to quantify the impact 
of co-morbid conditions on a large number of homogenous patients who had surgery for 
apparent early-stage endometrial cancer. With every increase in Charlson’s index by 1 point, 
the risk of a major AE rises by 15%.  
 The nomogram, as presented already accounts for the impact of surgical technique in the 
estimation of the risk of a major surgical AE. To provide a worked example, if a patient 
presents with a BMI of 32 kg/m2 (40 points) and a Charlson’s score of 6 (50 points), with 
grade 2 endometrioid adenocarcinoma on curettings (30 points), and ECOG functional score 
of 1 (30 points), with haemoglobin levels of 110 g/L (70 points), the total points are 210 for a 
patients receiving a TLH, and 248 for a patient receiving TAH. This reflects a risk of major 
AE of 30% compared to 50% for this patient if surgery is conducted by TLH compared to 
TAH, respectively. Thus, everything else being equal, the nomogram (as presented) can used 
to guide treatment choice if risk of surgical AE is a major factor. 
Some limitations to the present analysis are acknowledged. In the LACE trial, surgical AEs 
were a predefined secondary endpoint. While we collected data on some important risk 
factors leading to surgical AEs, other potential confounding factors, such as history of 
previous abdominal/pelvic surgery, surgeon’s experience, and organizational factors were not 
collected. Patients enrolled in the LACE trial had to have clinical early-stage disease, uterus 
size less than 10 weeks gestation and had to be fit for surgery with an ECOG score of not 
higher than 1. Therefore, our prediction model is not applicable to patients presenting with 
advanced stage endometrial cancer or to patients with poor preoperative ECOG performance 
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score, and also needs to be validated on an independent dataset to confirm its utility. Finally, 
the risk prediction tool developed within the present study still needs to be validated on an 
independent sample.  
In summary, our manuscript offers a new approach to quantifying the risk for major AEs in 
individual patients who require surgery for apparent early-stage endometrial cancer. These 
findings may allow gynecological oncologists to better predict the probability of major AEs 
in individual patients. In the future, the nomogram may also be used for comparison of risk 
adjusted adverse outcomes between health care institutions and also over time within the 
same institution.  
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Table 1: Patient characteristics (reproduced from Obermair et al submission) 
  TLH 
n=404  
TAH 
n=349  
Age < 50 years n(%) 35 (8.7) 32 (9.2) 
BMI, kg/m2   
Normal (<25 kg/m2), n(%) 47 (12.1) 46 (13.6) 
Overweight (25 to <30kg/m2), n(%) 97 (25.0) 72 (21.3) 
Obesity Class I (30 to <35 kg/m2), n(%) 77 (19.8) 86 (25.4) 
Obesity Class II (35 to <40 kg/m2), n(%) 81 (20.9) 61 (18.1) 
Obesity Class III (40+ kg/m2), n(%) 86 (22.2) 73 (21.6) 
   
Charlson’s Index (mean, SD) 3.0 (1.8) 2.9 (1.8) 
   
Nodal dissection, n (%)   
   Any 161/404 (39.9) 210/349 (60.2) 
   Pelvic 147/161 (91.3) 205/210 (97.6) 
   Aortic  11/161 (6.8)  43/210 (20.5) 
   Other (not specified) 13/161 (8.1) 16/210 (7.6) 
   
Grade on curettings, n(%)   
   1 258 (63.8) 220 (63.0) 
   2 119 (29.5) 106 (30.4) 
   3 27 (6.7) 23 (6.6) 
   
ECOG, n(%)   
   0 349 (86.4) 299 (85.7) 
   1 55 (13.6) 50 (14.3) 
   
Blood tests, mean (SD)   
   Haemoglobin, g/dL 135.9 (11.8) 134.4 (12.9) 
   Platelet count,  109/L 278.5 (71.6) 280.5 (69.7) 
   Neutrophil count,  109/La 1.5 (0.37) 1.5 (0.33) 
   White cell count, 109/L 7.8 (2.1) 7.9 (2.1) 
   Haematocrit 0.41 (0.04) 0.41 (0.04) 
   CA-125, U/mla 2.9 (0.83) 2.8 (0.86) 
Abbreviations: TLH = total laparoscopic hysterectomy; TAH=total abdominal hysterectomy; BMI: Body Mass 
Index; ECOG: Eastern Cooperative Oncology Group;  
Results are log(natural) transformed. 
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Table 2: Pre-surgical factors associated with risk of developing major AEs after surgery 
for apparently early stage endometrial cancer  
  Odds  ratio 95% confidence interval p-value 
   Lower limit Upper limit  
Planned surgical approach     
TLH Ref    
TAH 1.73 1.18 2.53 0.01 
     
Age at diagnosis 1.01 0.99 1.03 0.48 
BMI      
Normal (<25 kg/m2) Ref    
  Overweight (25 to <30kg/m2) 1.40 0.61 3.17 0.43 
  Obesity Class I (30 to <35 
kg/m2) 
2.11 0.95 4.65 0.07 
  Obesity Class II (35 to <40 
kg/m2) 
2.29 1.03 5.11 0.04 
  Obesity Class III (40+ kg/m2) 2.73 1.25 5.97 0.01 
     
Charlson’s Index 1.17 1.05 1.30 0.01 
     
Grade of differentiation on 
curettings 
    
1 Ref    
2 1.60 1.07 2.39 0.02 
3 1.81 0.90 3.63 0.10 
ECOG     
0 Ref - - - 
1 2.40 1.51 3.83 0.01 
     
Blood tests (prior to surgery)     
  Haemoglobin, g/dL 0.98 0.97 1.00 0.01 
  Haematocrit < 40% 1.46 0.99 2.14 0.06 
  Platelet count < 150  X 109/L 1.35 0.28 6.57 0.71 
  Aspartate transaminase  > 34 
IU/L 
1.80 1.08 3.00 0.02 
  Alkaline Phosphatase, > 140 
IU/L 
0.99 0.33 2.96 0.99 
  White cell count X 109/L 1.03 0.94 1.13 0.54 
  Creatinine 1.01 1.00 1.01 0.19 
  Bilirubina 0.97 0.71 1.31 0.82 
  Albumin 0.99 0.98 1.01 0.38 
Abbreviations: BMI: Body Mass Index; ECOG: Eastern Cooperative Oncology Group; a Log(natural) 
transformed   
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Table 3. Multivariate model predicting major AEs after surgery for apparently early 
stage endometrial cancer 
Odds Ratio 95% CI p-value 
Laparotomy vs laparoscopy 1.88 1.25 2.81 0.01 
Charlson's score 1.15 1.02 1.29 0.02 
Grade of differentiation on 
curettings 
  Grade 1 Ref 
  Grade 2 1.67 1.08 2.58 0.02 
  Grade 3 1.98 0.93 4.23 0.08 
ECOG (1 vs 0) 1.64 0.97 2.78 0.07 
BMI 
  Normal (<25 kg/m2) Ref 
  Overweight (25 to <30kg/m2) 1.41 0.61 3.28 0.42 
  Obesity Class I (30 to <35 kg/m2) 1.95 0.86 4.42 0.11 
  Obesity Class II (35 to <40 kg/m2) 2.45 1.06 5.64 0.04 
  Obesity Class III (40+ kg/m2) 2.69 1.19 6.09 0.02 
Haemoglobin 0.98 0.97 1.00 0.03 
Abbreviations: ECOG=Eastern Cooperative Oncology Group. BMI=Body Mass Index.  
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Figure 1. Nomogram to predict the risk of a major surgical adverse event after surgery 
for apparent early stage endometrial cancer  
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Figure 2. Calibration plot showing predicted probabilities and observed incidence of 
major adverse events 
0.0 0.2 0.4 0.6 0.8
0.
0
0.
2
0.
4
0.
6
0.
8
Predicted incidence of an AE
O
bs
er
ve
d 
in
ci
de
nc
e 
of
 a
n 
A
E
Nomogram predicted
Ideal
 
 
  
19 
 
References: 
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 
v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. In. 
Lyon, France: International Agency for Research on Cancer; 2010. 
2. Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, et al. 
Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-
control study. Am J Obstet Gynecol 1992;167(5):1317-25. 
3. Lindemann K, Vatten LJ, Ellstrom-Engh M, Eskild A. Body mass, diabetes and 
smoking, and endometrial cancer risk: a follow-up study. Br J Cancer 2008;98(9):1582-5. 
4. Soler M, Chatenoud L, Negri E, Parazzini F, Franceschi S, la Vecchia C. 
Hypertension and hormone-related neoplasms in women. Hypertension 1999;34(2):320-5. 
5. Weiderpass E, Persson I, Adami HO, Magnusson C, Lindgren A, Baron JA. Body size 
in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal 
endometrial cancer (Sweden). Cancer Causes Control 2000;11(2):185-92. 
6. Lewin SN, Herzog TJ, Barrena Medel NI, Deutsch I, Burke WM, Sun X, et al. 
Comparative performance of the 2009 international Federation of gynecology and obstetrics' 
staging system for uterine corpus cancer. Obstet Gynecol 2010;116(5):1141-9. 
7. Janda M, Gebski V, Brand A, Hogg R, Jobling TW, Land R, et al. Quality of life after 
total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial 
cancer (LACE): a randomised trial. Lancet Oncol 2010;11(8):772-80. 
8. Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et 
al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine 
cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol 2009;27(32):5331-6. 
9. Mourits MJ, Bijen CB, Arts HJ, ter Brugge HG, van der Sijde R, Paulsen L, et al. 
Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised 
trial. Lancet Oncol 2010;11(8):763-71. 
10. Janda M, Gebski V, Forder P, Jackson D, Williams G, Obermair A. Total 
laparoscopic versus open surgery for stage 1 endometrial cancer: the LACE randomized 
controlled trial. Contemp Clin Trials 2006;27(4):353-63. 
11. McCartney AJ, Obermair A. Total laparoscopic hysterectomy with a transvaginal 
tube. J Am Assoc Gynecol Laparosc 2004;11(1):79-82. 
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying 
prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 
1987;40(5):373-83. 
13. Friese CR, Aiken LH. Failure to rescue in the surgical oncology population: 
implications for nursing and quality improvement. Oncol Nurs Forum 2008;35(5):779-85. 
14. Kondalsamy-Chennakesavan S, Bouman C, De Jong S, Sanday K, Nicklin J, Land R, 
et al. Clinical audit in gynecological cancer surgery: development of a risk scoring system to 
predict adverse events. Gynecol Oncol 2009;115(3):329-33. 
15. Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, Lawthers AG, et al. 
Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard 
Medical Practice Study I. N Engl J Med 1991;324(6):370-6. 
16. Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, et al. The 
nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice 
Study II. N Engl J Med 1991;324(6):377-84. 
17. Khuri SF, Henderson WG, Daley J, Jonasson O, Jones RS, Campbell DA, Jr., et al. 
Successful implementation of the Department of Veterans Affairs' National Surgical Quality 
Improvement Program in the private sector: the Patient Safety in Surgery study. Ann Surg 
2008;248(2):329-36. 
20 
 
18. Ghebre RG, Posthuma R, Vogel RI, Geller MA, Carson LF. Effect of age and 
comorbidity on the treatment and survival of older patients with vulvar cancer. Gynecol 
Oncol 2011;121(3):595-9. 
19. O'Malley RL, Hayn MH, Hellenthal NJ, Kim HL, Underwood Iii W, Schwaab T. 
Safety and outcomes of surgical treatment of renal cell carcinoma in the elderly. Can J Urol 
2012;19(1):6111-7. 
20. Tian WJ, Chi DS, Sehouli J, Trope CG, Jiang R, Ayhan A, et al. A risk model for 
secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for 
patient selection. Ann Surg Oncol 2012;19(2):597-604. 
21. Chow PK, Machin D, Chen Y, Zhang X, Win KM, Hoang HH, et al. Randomised 
double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular 
carcinoma. Br J Cancer 2011;105(7):945-52. 
22. Korfel A. Prevention of central nervous system relapses in diffuse large B-cell 
lymphoma: which patients and how? Current opinion in oncology 2011;23(5):436-40. 
23. Moon KY, Chung CK, Jahng TA, Kim HJ, Kim CH. Postoperative survival and 
ambulatory outcome in metastatic spinal tumors: prognostic factor analysis. J Korean 
Neurosurgical Society 2011;50(3):216-23. 
24. Park HS, Rha SY, Kim HS, Hyung WJ, Park JS, Chung HC, et al. A prognostic model 
to predict clinical outcome in gastric cancer patients with bone metastasis. Oncology 
2011;80(1-2):142-50. 
25. Holtz G. Laparoscopy in the massively obese female. Obstet Gynecol 1987;69(3 Pt 
1):423-4. 
26. O'Gorman T, MacDonald N, Mould T, Cutner A, Hurley R, Olaitan A. Total 
laparoscopic hysterectomy in morbidly obese women with endometrial cancer anaesthetic 
and surgical complications. Eur J Gynaecol Oncol 2009;30(2):171-3. 
 
 
